Abstract
Chemotherapy is widely used in the management of patients with advanced breast cancer. However, a considerable proportion of patients experience toxic side effects without gaining benefit. This study aimed to elicit oncologists' views of the goals of chemotherapy for patients with advanced breast cancer and to elicit which factors are important in decisions to recommend chemotherapy to such patients. 30 oncologists underwent a semi-structured interview to examine their views of 5 goals of chemotherapy and of various disease, treatment and patient-related factors that might influence decisions to offer treatment. The clinicians also made decisions regarding treatment in relation to a hypothetical patient scenario under varying clinical conditions. Relief of symptoms and improvement of activity were rated as the most valuable and achievable goals of treatment. The patient's performance status, frailty and their wishes regarding treatment were the most important patient-related factors in determining decision-making. The most important disease/treatment-related factors were pace of the disease, previous poor response to chemotherapy, co-existing symptoms and concurrent medical conditions. The hypothetical scenario revealed that co-existing medical conditions, adverse previous response, increased age and depression would decrease the likelihood of recommending chemotherapy, whereas key symptoms (e.g. breathlessness) and the patient's goals would increase the likelihood. The findings suggest that British oncologists primarily aim to improve patients' physical function, although subjective factors, such as a patient's desire for anti-cancer treatment and their future goals, also influence decisions to offer treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baum M, Priestman T, West R and Jones E (1980) A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Proceedings of the Second EORTC Breast Cancer Working Conference, 223–226, Pergamon Press: Oxford
Benner SE, Fetting JH and Brenner MH (1994) A stopping rule for standard chemotherapy for metastatic breast cancer: lessons from a survey of Maryland oncologists. Cancer Invest 12: 451–455
Derber RB and Thompson GG (1990) Variations in breast cancer: lessons treatment decisions and their impact in mounting trials. Control Clinical Trials 11: 353–373
Dodwell DJ, Rathmell AJ and Ash DV (1993) Assessment of palliative chemotherapy: a step beyond response. Clin Oncol 5: 114–117
Edwards W (1954) The Theory of Decision Making. Psychol Bull 51: 380–417
Falkson G, Gelman R, Ralkson CI, Glick J and Harris J (1991) Factors predicting response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective eastern co-operative oncology group study. J Clin Oncol 9: 2153–2161
Geels P, Eisenhauer E, Bezjak A, Zee B and Day A (2000) Palliative chemotherapy: objective tumour response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395–2405
Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK and Rubens RD (1993) Chemotherapy of advanced cancer: outcome and prognostic factors. British Journal of Cancer 68: 988–995
Leonard RCF, Rodger A and Dixon JM (1995) Metastatic breast cancer. Dixon JM (ed). ABC of Breast Diseases, pp. 45–48, BMJ Publishing Group: London
Maher EJ and Jefferis AF (1990) Decision making in advanced cancer of the head and neck: variation in the views of medical specialists. Journal of the Royal Society of Medicine 83: 356–359
Maher EJ, Coia L, Duncan G and Lawton PA (1992) Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Phys 23: 239–244
Markman M (1997) Salvage chemotherapy of malignant disease: importance of precisely defining goals of treatment. Cancer Res Clin Oncol 123: 467–468
McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM and Clark GM (1991) Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 70: 1775–1781
Namer M, Mercier M, Hurteloup P, Bonneterre J and Bastit P (1990) Prognostic factors of metastasised breast cancer patients. Breast Cancer Res and Treat 16: 60
Porzsolt F and Tannock I (1993) Goals of palliative cancer therapy. J Clin Oncol 11: 378–381
Ramirez AJ, Towlson KE, Leaning MS, Richards MA and Rubens RD (1998) Do patients with advanced breast cancer benefit from chemotherapy?. British Journal of Cancer 78: 1488–1494
Rubens RD, Towlson KE, Ramirez AJ, Coltart S, Slevin ML, Terrell C and Timothy AR (1992) Appropriate chemotherapy for palliating advanced cancer. BMJ 304: 35–40
Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ and Downer SM (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 300: 1458–1460
Stanton AL, Stanton AL, Estes MA, Estes NC, Cameron CL, Danoff-Burg S and Irving LM (1998) Treatment decision making and adjustment to breast cancer: a longitudinal study. Journal of Consulting and Clinical Psychology 66: 313–322
Stoll BA (1990) Choosing between cancer patients. Journal of Medical Ethics 16: 71–74
Sutherland HJ, Lockwood GA and Boyd NF (1990) Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 43: 661–666
Tversky A (1967) Additivity, utility and subjective probability. Journal of Mathematical Psychology 4: 175–201
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Grunfeld, E., Ramirez, A., Maher, E. et al. Chemotherapy for advanced breast cancer: what influences oncologists' decision-making?. Br J Cancer 84, 1172–1178 (2001). https://doi.org/10.1054/bjoc.2001.1733
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1733
Keywords
This article is cited by
-
Patients’ understanding of treatment goals and disease course and their relationship with optimism, hope, and quality of life: a preliminary study among advanced breast cancer outpatients before receiving palliative treatment
Supportive Care in Cancer (2016)
-
Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors
Breast Cancer Research and Treatment (2013)
-
Controversies on the management of clinical situations with low therapeutic effectiveness in oncology
Clinical and Translational Oncology (2010)
-
Letrozole in advanced breast cancer: the PO25 trial
Breast Cancer Research and Treatment (2007)
-
The patient experience
Breast Cancer Research and Treatment (2007)